Review article: Diagnosis and treatment of non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2008, Pages 503-522

  Oh, M K ^b   Winn, J ^b   Poordad, F ^a,c  

^a Cedars Sinai Medical Center ^*  (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Ctr for Liver Dis/Transplantation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIRETROVIRUS AGENT; ASPARAGINASE; ATORVASTATIN; AZACITIDINE; AZASERINE; AZAURIDINE; BETAINE; BLEOMYCIN; ESTROGEN DERIVATIVE; GEMFIBROZIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; METHOTREXATE; NATEGLINIDE; PENTOXIFYLLINE; PIOGLITAZONE; PRAVASTATIN; PUROMYCIN; ROSIGLITAZONE; ROSUVASTATIN; TAMOXIFEN; TETRACYCLINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIAGNOSTIC PROCEDURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INDUSTRIALIZATION; INFLAMMATION; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; MORBIDITY; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; AGED; ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; UP-REGULATION;

EID: 48449103834     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03752.x     Document Type: Review

References (177)

1. Werswater JD, Fainer D. Liver impairment in the obese. Gastroenterology 1958 34 : 686 93.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 55 : 434 8.
3. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/overweight/ overwght_adult_03.htm (last accessed 2 April 2008).
4. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999 107 : 450 5.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 9.
6. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002 283 : E413 22.
7. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000 106 : 171 6.
8. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001 414 : 799 806.
9. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthetase kinase-3 by insulin mediated by protein kinase B. Nature 1995 378 : 385 9.
10. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci U S A 1996 93 : 1049 53.
11. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006 131 : 934 45.
12. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK dependent hepatocyte apoptosis. J Biol Chem 2006 281 : 12093 191.
13. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004 40 : 185 94.
14. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006 290 : 1339 46.
15. Wei Y, Wang D, Pagliassotti MJ. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Mol Cell Biochem 2007 303 : 105 13.
16. Raucy JL, Lasker J, Ozaki K, Zoleta V. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 2004 79 : 233 41.
17. Li Z, McIntyre T, Feldstein AE. Free fatty acids induce hepatocyte mitochondrial dysfunction in a lysosomal-dependent fashion: A link between steatosis and liver injury. Gastroenterology 2006 130 : A762.
18. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007 25 : 883 9.
19. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000 132 : 112 7.
20. Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis:summary of AASLD single topic conference. Hepatol 2003 37 : 1202 19.
21. Dixon JB. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001 121 : 91 100.
22. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-y gastric bypass. Obes Surg 2002 12 : 49 51.
23. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003 124 : 71 9.
24. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatol 2004 40 : 1387 95.
25. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004 8 : 521 33.
26. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007 11 : 25 35.
27. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004 53 : 750 5.
28. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 : 113 21.
29. Papdia F, Marinari G, Camerini G, et al. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1000 liver biopsies. Obes Surg 2004 14 : 952 8.
30. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000 118 : 1117 23.
31. Tsang S, Ng W, Wu B, et al. Predictors of fibrosis in Asian patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006 21 : 116 21.
32. Seth S, Flamm S, Gordon F, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 1998 93 : 44 8.
33. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999 30 : 1356 62.
34. Brunt EM, Neuschwander-Tetri BA, Oliver D, et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Human pathol 2004 35 : 1070 82.
35. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004 39 : 179 87.
36. Gramlich T, Kleiner DE, McCullogh AJ, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Human Pathol 2004 35 : 196 9.
37. Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002 24 : 429 38.
38. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006 40 : S34 8.
39. Bondini S, Kleiner DE, Goodman ZD, et al. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007 11 : 17 23.
40. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 21.
41. Brunt E. Nonalcoholic steatohepatitis. Semin Liv Dis 2004 24 : 3 20.
42. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006 44 : 874 80.
43. Larson SP, Bowers SP, Palekar NA, et al. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol 2007 5 : 1329 32.
44. Arun J, Jhala N, Lazenby AJ, et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 2007 17 : 155 61.
45. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005 128 : 1898 906.
46. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007 11 : 37 54.
47. Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007 4 : 432 41.
48. Ryan CK, Johnson LA, Germin BI, et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002 8 : 1114 22.
49. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004 14 : 635 7.
50. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007 189 : W320 3.
51. Von Herbay A, Frieling T, Haussinger D. Association between duplex doppler sonographic flow pattern in right hepatic vein and various liver diseases. J Clin Ultrasound 2001 29 : 25 30.
52. Dietrich CF, Lee JH, Gottschalk R, et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. Am J Roentgenol 1998 171 : 437 43.
53. Oguzkurt L, Yildirim T, Torun D, et al. Hepatic vein doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol 2005 54 : 253 7.
54. Kawata R, Sakata K, Kunieda T, et al. Quantitative evaluation of fatty liver by computed tomography in rabbits. Am J Roentgenol 1984 142 : 741 6.
55. Oliva MR, Mortele KJ, Segatto E, et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006 30 : 37 43.
56. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002 123 : 745 50.
57. Mendler MH, Bouillet P, Le Sidaner A, et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in the comparison to ultrasound scan and single energy CT, with special reference to iron overload. J Hepatol 1998 28 : 785 94.
58. Chave G, Milot L, Pilleul F. Out of phase magnetic resonance imaging and liver applications. J Radiol 2005 86 : 993 7.
59. Qayyum A, Goh JS, Dakar S, et al. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. Radiology 2005 237 : 507 11.
60. Valls C, Iannacconne R, Alba E, et al. Fat in the liver: diagnosis and characterization. Eur Radiol 2006 16 : 2292 308.
61. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007 46 : 582 9.
62. Miele L, Forgione A, Gasbarrini G, et al. Noninvasive assessment of fibrosis in nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 2007 149 : 114 25.
63. Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005 100 : 2438 46.
64. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 : 46 54.
65. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006 26 : 39 45.
66. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003 38 : 413 9.
67. Yoneda M, Mawatari H, Fujita L, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also the severity of fibrosis in NASH. J Gastroenterol 2007 42 : 573 82.
68. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and Fas expression are prominent features on human nonalcoholic steatohepatitis. Gastroenterology 2003 125 : 437 43.
69. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 : 27 33.
70. Mitry RR, De Bruyne R, Quaglia A, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers [Letter]. Hepatology 2007 46 : 2047 8.
71. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006 6 : 33 9.
72. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005 4 : 10 24.
73. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of nonalcolo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006 6 : 34 50.
74. Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007 102 : 1931 8.
75. Suzuki A, Angulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005 25 : 779 86.
76. Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006 26 : 151 6.
77. Degertegin B, Ozenirler S, Elbeg S, et al. Serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007 52 : 2622 8.
78. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008 134 : 8 14.
79. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008 40 : 371 8.
80. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007 56 : 968 73.
81. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (Fibroscan): a prospective study. Gut 2006 55 : 403 8.
82. Kim KM, Choi WB, Park SH, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007 42 : 382 8.
83. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that accurately identifies liver fibrosis in patients with NAFLD. Hepatology 2007 45 : 846 54.
84. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004 127 : 1704 13.
85. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the european liver fibrosis panel and exploring simple markers. Hepatology 2008 47 : 455 60.
86. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006 6 : 6.
87. Guha IN, Parkes J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006 55 : 1650 60.
88. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006 26 : 1021 8.
89. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow up of patients with NAFLD and elevated liver enzymes. Hepatology 2006 44 : 865 73.
90. Huang S, Czech M. The GLUT 4 glucose transporter. Cell Metab 2007 5 : 237 52.
91. Ueno T, Suguwara J, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997 27 : 103 7.
92. Tendler D, Lin S, Yancy WS. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007 52 : 589 93.
93. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005 100 : 1072 81.
94. Thomas EL, Brynes AE, Hamilton G, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006 12 : 5813 9.
95. Baba CS, Alexander GA, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006 21 : 191 8.
96. Okita M, Hayashi M, Sasagawa T, et al. Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001 17 : 542 7.
97. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002 123 : 1705 25.
98. Andersen T, Gluud C, Franzmann ME, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991 12 : 224 9.
99. Harrison SA, Fincke C, helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004 20 : 623 8.
100. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic finding, insulin resistance and liver enzymes in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003 12 : 189 92.
101. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004 14 : 1157 64.
102. Chapman A, Kiroff G, Game P, et al. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic review. Surgery 2004 135 : 326 51.
103. Dixon JB, O'Brien P. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002 25 : 358 63.
104. Dixon JB, O'Brien PE. Changes in comorbities and improvements in quality of life after Lap-Band placement. Am J Surg 2002 184 : S51 4.
105. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004 39 : 1647 54.
106. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007 17 : 486 92.
107. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005 242 : 610 20.
108. De Almeida SR, Rocha PR, Sanchea MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006 16 : 270 8.
109. Kral JG, Thung SW, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surg 2004 135 : 48 58.
110. Furuya CK, de Oliveira C, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease:preliminary findings after 2 years. J Gastroenterol Hepatol 2007 22 : 510 4.
111. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 1998 22 : 222 6.
112. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995 104 : 23 31.
113. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004 89 : 2728 35.
114. Lutchman G, Promrat G, Keiner DE, et al. Changes in serum adipokine levels during pioglitazone treatment of nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006 4 : 1048 52.
115. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 355 : 2297 307.
116. Ratziu V, Charlotte AF, Jacquemine S, et al. A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial. Hepatology 2006 44 (Suppl 1 201A.
117. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004 2 : 1107 15.
118. Akyuz F, Demir K, Ozdil S, et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci 2007 52 : 2359 67.
119. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004 39 : 188 96.
120. Neuschwander-Tetri BA, brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003 38 : 434 40.
121. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007 46 : 285 7.
122. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 71.
123. Nathan DM. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 357 2007 1 : 64 6.
124. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006 368 : 1096 105.
125. Grey A, Bolland M, Gamble G, et al. The Peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007 92 : 1305 10.
126. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 108 : 1167 74.
127. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled of metformin versus vitamin E on prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005 100 : 1082 90.
128. Ugyun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2004 19 : 537 44.
129. Duseja A, Das A, Dhiman RK, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007 6 : 222 6.
130. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcholic steatohepatitis. Lancet 2001 358 : 893 4.
131. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of nonalcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004 20 : 23 8.
132. Misbin RI, Green L, Stadel LG, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998 338 : 265 6.
133. Doyle M, Egan J. Pharmacologic agents that directly modulate insulin secretion. Pharmacol Rev 2003 55 : 105 31.
134. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exedin-4, a glucagon-like protein1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006 43 : 173 81.
135. Morita Y, Ueno T, Sasaki N, et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterol 2005 52 : 1338 43.
136. Vajro P, Madato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004 38 : 48 55.
137. Miller ER, Pastor-Barriuso R, Dalal D. High-Dosage Vitamin E supplementation may increase all-cause mortality. Ann Int Med 2005 142 : 37 46.
138. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, mulitcenter clinical trial. J Hepatol 1999 30 : 1081 9.
139. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001 96 : 2711 7.
140. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6,IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994 83 : 262 7.
141. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004 99 : 2365 8.
142. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastoenterology 2004 126 : 1287 92.
143. Roglans V, Verd JC, Peris C, et al. High doses of atorvastatin and simvistatin induce key enzymes involved in VLDL production. Lipids 2002 37 : 445 54.
144. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated enzymes: a histopathological follow-up study. J Hepatol 2007 47 : 135 41.
145. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003 17 : 713 8.
146. Ralladis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004 174 : 193 6.
147. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006 23 : 1643 7.
148. Antonopoulos S, Mikros S, Mylonopoulou M. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006 184 : 233 4.
149. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004 23 : 131 4.
150. Brown DF. The effect of ethyl alpha-p-chlorophenoxy isobutyrate on ethanol-induced hepatic steatosis in the rat. Metabolism 1966 15 : 868 73.
151. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996 23 : 1464 7.
152. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999 31 : 384.
153. Merat S, Aduli M, Sotoudeh M, et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2007 [Epub ahead of print].
154. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006 23 : 1143 51.
155. DiMarzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005 8 : 85 95.
156. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005 115 : 1298 305.
157. Mallat A, Teixeira-Clerc F, Deveaux V, et al. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver disease. Expert Opin Ther Targets 2007 11 : 403 9.
158. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007 131 : 728 1734.
159. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007 45 : 1375 81.
160. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001 34 : 745 50.
161. Yang L, Batalled R, Dulys J, et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005 43 : 317 23.
162. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007 52 : 3455 64.
163. Ibanez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2007 22 : 846 51.
164. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.
165. King LS, Kozono D, Agre P. From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 2004 5 : 687 98.
166. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G. The role of aquaporin-7 in the pathophysiological control of fat accumulation in mice. FEBS Lett 2006 580 : 4771 6.
167. Kuriyama H, Shimomura I, Kishida K, et al. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 2002 51 : 2915 21.
168. Cope K, Risby T, Diehl AM. Increased gastrointestinal production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000 119 : 1340 7.
169. Li A, Yang S, Huang H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003 37 : 343 50.
170. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005 39 : 540 3.
171. Capozza F, Combs TP, Cohen AW, et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol 2005 288 : C1317 31.
172. Razani B, Combs TP, Wang XB, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002 277 : 8625 47.
173. Cohen AW, Razani B, Wang XB, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 2003 285 : C222 35.
174. Daubioul CA, Taper HS, DeWispelaere LD, Delzenne NM. Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese zucker rats. J Nutr 2000 130 : 1314 9.
175. Agheli N, Kabir M, Berni-Canani S, et al. Plasma lipids and fatty acids synthase activity are regulated by short chain fructooligosaccharides in sucrose-fed insulin-resistant rats. J Nutr 1998 128 : 1283 8.
176. Kok N, Roberfroid M, Robert A, Delzenne NM. Involvement of lipogenesis in the lower VLDL secretion induced by oligofructose in rats. Br J Nutr 1996 76 : 881 90.
177. Daubioul CA, Horsman Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005 59 : 723 6.